TIGIT Antibody / VSTM3 / VSIG9

ELISA (order BSA/sodium azide-free format for coating),Immunohistochemistry (FFPE): 1-2ug/ml for 30 min at RT

Optimal dilution of the TIGIT antibody should be determined by the researcher.
1. The prediluted format is supplied in a dropper bottle and is optimized for use in IHC. After epitope retrieval step (if required), drip mAb solution onto the tissue section and incubate at RT for 30 min.

TIGIT is a checkpoint inhibitor which binds with high affinity to the poliovirus receptor (PVR), causing increased IL10 secretion, decreased IL12B secretion. TIGIT binding to PVR also causes the suppression of T cell activation by promoting the generation of mature immuno-regulatory dendritic cells. It is expressed at low levels on natural killer (NK) cells, as well as peripheral memory and regulatory CD4+ T cells. At the protein level, it is upregulated following the activation of these cells. Functionally, TIGIT is similar to CTLA4. The ligands for TIGIT include CD155 (signal abrogation) and CD226 (signal stimulation). It has been demonstrated to be upregulated on T cells in many cancers and is a immuno-oncology target for therapy.

Purified

0.2 mg/ml in 1X PBS with 0.1 mg/ml BSA (US sourced) and 0.05% sodium azide

A recombinant human TIGIT protein fragment within amino acids 194-244 was used as the immunogen for the TIGIT antibody.

This TIGIT antibody is available for research use only.

Yes

Protein G affinity chromatography

Human

Q495A1